Genmab A/S (NASDAQ:GMAB) Stock Price Target Raised at Guggenheim

Genmab A/S (NASDAQ:GMAB) had its price target hoisted by analysts at Guggenheim from $58.00 to $80.00 in a report released on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim‘s target price would suggest a potential upside of 38.09% from the company’s current price.

A number of other research analysts have also weighed in on GMAB. TD Cowen lifted their target price on Genmab A/S from $43.00 to $52.00 and gave the company a “buy” rating in a report on Monday. Truist Financial reiterated a “buy” rating and set a $67.00 price objective (up from $45.00) on shares of Genmab A/S in a research report on Thursday. Morgan Stanley set a $42.00 target price on Genmab A/S in a research note on Tuesday, October 20th. New Street Research set a $43.00 price target on Genmab A/S in a research report on Wednesday, July 22nd. Finally, JPMorgan Chase & Co. upgraded shares of Genmab A/S from a “neutral” rating to an “overweight” rating in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Genmab A/S currently has a consensus rating of “Moderate Buy” and an average price target of $51.94.

Genmab A/S Stock Performance

Genmab A/S stock opened at $57.93 on Friday. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.46 and a quick ratio of 2.44. The business has a 50 day moving average of $36.64 and a 200-day moving average of $30.47. Genmab A/S has a 1 year low of $23.62 and a 1 year high of $59.97. The company has a market capitalization of $36.15 billion, a P/E ratio of 46.24, a P/E/G ratio of 2.47 and a beta of 0.81.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.17. The business had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.12 billion. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. On average, equities research analysts predict that Genmab A/S will post 1.22 earnings per share for the current year.

Institutional Trading of Genmab A/S

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. WINTON GROUP Ltd lifted its position in shares of Genmab A/S by 158.9% during the 2nd quarter. WINTON GROUP Ltd now owns 40,900 shares of the company’s stock valued at $1,124,000 after buying an additional 25,100 shares in the last quarter. Diversify Wealth Management LLC purchased a new stake in Genmab A/S in the 1st quarter worth approximately $1,216,000. SummitTX Capital L.P. purchased a new stake in Genmab A/S in the 1st quarter worth approximately $2,263,000. Legacy Wealth Asset Management LLC raised its stake in Genmab A/S by 164.1% during the 2nd quarter. Legacy Wealth Asset Management LLC now owns 102,164 shares of the company’s stock worth $2,806,000 after acquiring an additional 63,484 shares during the period. Finally, Y Intercept Hong Kong Ltd purchased a new position in Genmab A/S during the first quarter valued at approximately $1,198,000. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Key Genmab A/S News

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Promising Phase 3 cancer data: Petosemtamab, combined with Merck’s Keytruda, delivered a statistically significant and clinically meaningful improvement in overall survival and objective response in first-line recurrent or metastatic head and neck cancer. Reports indicated the treatment reduced the risk of death by approximately 50%, strengthening the drug’s potential commercial value and supporting Genmab’s oncology pipeline. Genmab announces petosemtamab Phase 3 results
• Positive Sentiment: Higher analyst targets: HC Wainwright raised its price target from $50 to $70 and reaffirmed a Buy rating, while Truist increased its target from $45 to $67 and also maintained a Buy rating. The upgrades reflect increased confidence in Genmab’s growth prospects following the trial results. HC Wainwright price target
• Positive Sentiment: Potential for a new treatment standard: Commentary surrounding the Phase 3 results suggests petosemtamab could become an important treatment option in head and neck cancer if the data are confirmed and regulatory requirements are met. Genmab Phase 3 cancer data transcript
• Neutral Sentiment: Limited earnings-estimate changes: HC Wainwright’s quarterly EPS forecasts were largely unchanged, with a modest increase for third-quarter 2027 to $0.61 from $0.60. The firm continues to rate GMAB Buy with a $70 target, while consensus full-year EPS is $1.22.
• Negative Sentiment: Valuation and execution risks: After the sharp move higher, some commentary argues investors should wait before buying, highlighting the need for regulatory progress, successful commercialization and further validation of the trial results. Why wait before buying Genmab

About Genmab A/S

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins.

Genmab’s marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen.